1. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.

    European Journal of Cancer 51(12):1603 (2015) PMID 26037152

    MED12 is a subunit of the multiprotein complex Mediator, an evolutionary-conserved regulator of transcription. Oncogenic mutations in exon 2 of MED12 occur in nearly 70% of uterine leiomyomas, and together with HMGA, represent the most common genetic anomalies in leiomyoma. This mutational anoma...
  2. Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma.

    Journal of Clinical Oncology 33(20):e84 (2015) PMID 24687827

  3. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.

    Modern Pathology 28(7):1001 (2015) PMID 25932961

    The diagnosis and management of uterine smooth muscle tumors with uncertain malignant potential (STUMP) is often challenging, and genomic data on these lesions as well as on uterine smooth muscle lesions are limited. We tested the hypothesis that genomic profile determination by array-CGH could ...
  4. Myxoid Liposarcoma With Heterologous Components: Dedifferentiation or Metaplasia? A FISH-documented and CGH-documented Case Report.

    Applied Immunohistochemistry 23(3):230 (2015) PMID 25747531

    Heterologous differentiation in myxoid liposarcoma is a rare phenomenon. Few cases have been reported thus far, often without molecular assays, and the concept of "dedifferentiated" myxoid liposarcoma remains controversial. We describe a primary myxoid liposarcoma with chondroid and osseous comp...
  5. Myxoid Liposarcoma With Heterologous Components: Dedifferentiation or Metaplasia? A FISH-documented and CGH-documented Case Report.

    Applied Immunohistochemistry 23(3):230 (2015) PMID 25747531

    Heterologous differentiation in myxoid liposarcoma is a rare phenomenon. Few cases have been reported thus far, often without molecular assays, and the concept of "dedifferentiated" myxoid liposarcoma remains controversial. We describe a primary myxoid liposarcoma with chondroid and osseous comp...
  6. Nuclear-Receptor-Mediated Telomere Insertion Leads to Genome Instability in ALT Cancers

    Cell 160(5):913 (2015)

    The breakage-fusion-bridge cycle is a classical mechanism of telomere-driven genome instability in which dysfunctional telomeres are fused to other chromosomal extremities, creating dicentric chromosomes that eventually break at mitosis. Here, we uncover a distinct pathway of telomere-...
  7. Nuclear-Receptor-Mediated Telomere Insertion Leads to Genome Instability in ALT Cancers

    Cell 160(5):913 (2015) PMID 25723166

    The breakage-fusion-bridge cycle is a classical mechanism of telomere-driven genome instability in which dysfunctional telomeres are fused to other chromosomal extremities, creating dicentric chromosomes that eventually break at mitosis. Here, we uncover a distinct pathway of telomere-...
  8. Nuclear-Receptor-Mediated Telomere Insertion Leads to Genome Instability in ALT Cancers.

    Cell 160(5):913 (2015) PMID 25723166

    The breakage-fusion-bridge cycle is a classical mechanism of telomere-driven genome instability in which dysfunctional telomeres are fused to other chromosomal extremities, creating dicentric chromosomes that eventually break at mitosis. Here, we uncover a distinct pathway of telomere-driven gen...
  9. Fluorescence in situ hybridization analysis is a helpful test for the diagnosis of dermatofibrosarcoma protuberans.

    Modern Pathology 28(2):230 (2015) PMID 25081750

    Cytogenetically, most dermatofibrosarcoma protuberans are characterized by chromosomal rearrangements resulting in the collagen type-1 alpha 1 (COL1A1)-platelet-derived growth factor β (PDGFB) fusion gene. This abnormality can be detected by fluorescence in situ hybridization (FISH) analysis in ...
  10. Fluorescence in situ hybridization analysis is a helpful test for the diagnosis of dermatofibrosarcoma protuberans.

    Modern Pathology 28(2):230 (2015) PMID 25081750

    Cytogenetically, most dermatofibrosarcoma protuberans are characterized by chromosomal rearrangements resulting in the collagen type-1 alpha 1 (COL1A1)-platelet-derived growth factor β (PDGFB) fusion gene. This abnormality can be detected by fluorescence in situ hybridization (FISH) analysis in ...
  11. [Molecular biology for sarcoma: Useful or necessary?].

    Annales de Pathologie 35(1):107 (2015) PMID 25533919

    Sarcomas are a heterogeneous group of tumors. Their diagnosis is based on morphology and immunohistochemical profile, with categories of tumors according to the type of tissue that they resemble. Nevertheless, for several tumors, cellular origin is unknown. Molecular analysis performed in recent...
  12. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.

    European Journal of Cancer 51(1):75 (2015) PMID 25466504

    Imatinib mesylate is the front-line targeted therapy for gastrointestinal stromal tumours (GISTs). Patient's eligibility to adjuvant imatinib after primary tumour resection is currently based on histological and clinical risk assessment. While therapeutic options are clear for the very-low, low ...
  13. [Molecular biology for sarcoma: useful or necessary?].

    Annales de Pathologie 35(1):107 (2015) PMID 25533919

    Sarcomas are a heterogeneous group of tumors. Their diagnosis is based on morphology and immunohistochemical profile, with categories of tumors according to the type of tissue that they resemble. Nevertheless, for several tumors, cellular origin is unknown. Molecular analysis performed in recent...
  14. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.

    European Journal of Cancer 51(1):75 (2015) PMID 25466504

    Imatinib mesylate is the front-line targeted therapy for gastrointestinal stromal tumours (GISTs). Patient's eligibility to adjuvant imatinib after primary tumour resection is currently based on histological and clinical risk assessment. While therapeutic options are clear for the very-low, low ...
  15. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.

    European Journal of Cancer 51(1):75 (2015) PMID 25466504

    Imatinib mesylate is the front-line targeted therapy for gastrointestinal stromal tumours (GISTs). Patient's eligibility to adjuvant imatinib after primary tumour resection is currently based on histological and clinical risk assessment. While therapeutic options are clear for the very-low, low ...
  16. Biologie moléculaire en pathologie des tissus mous : utile ou nécessaire ?

    Annales de Pathologie (2014)

    Les sarcomes sont un groupe hétérogène de tumeurs dont le diagnostic repose sur la morphologie et le profil immunohistochimique, avec des catégories de tumeurs en fonction du tissu dont elles semblent dériver. Cependant pour de nombreuses tumeurs, l’origine cellulaire est inconnue. Les...
  17. Biologie moléculaire en pathologie des tissus mous : utile ou nécessaire ?

    Annales de Pathologie (2014)

    Les sarcomes sont un groupe hétérogène de tumeurs dont le diagnostic repose sur la morphologie et le profil immunohistochimique, avec des catégories de tumeurs en fonction du tissu dont elles semblent dériver. Cependant pour de nombreuses tumeurs, l’origine cellulaire est inconnue. Les...
  18. Biologie moléculaire en pathologie des tissus mous : utile ou nécessaire ?

    Annales de Pathologie (2014)

    Les sarcomes sont un groupe hétérogène de tumeurs dont le diagnostic repose sur la morphologie et le profil immunohistochimique, avec des catégories de tumeurs en fonction du tissu dont elles semblent dériver. Cependant pour de nombreuses tumeurs, l’origine cellulaire est inconnue. Les...
  19. MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors.

    International Journal of Cancer 135(2):348 (2014) PMID 24375455

    Liposarcomas are rare, heterogeneous and malignant tumors that can be divided into four histological subtypes with different characteristics and clinical behavior. Treatment consists of surgery in combination with systemic chemotherapy, but nevertheless mortality rates are high. More insight int...
  20. MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors.

    International Journal of Cancer 135(2):348 (2014) PMID 24375455

    Liposarcomas are rare, heterogeneous and malignant tumors that can be divided into four histological subtypes with different characteristics and clinical behavior. Treatment consists of surgery in combination with systemic chemotherapy, but nevertheless mortality rates are high. More insight int...